The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with Covid-19, said a World Health Organization (WHO) Guideline Development Group of international experts in The BMJ medical journal on Sept 16 (2022).

These drugs work by binding to the SARS-CoV-2 spike protein, neutralising the virus’s ability to infect cells.